127 results about "Tumor growth inhibition" patented technology

The present invention relates to an immuno-therapy conjugate which comprises A-c-B wherein: A and B are different and are compounds selected from the group consisting of cytokines, chemokines, interferons, their respective receptors or a functional fragment thereof; and c is a linker consisting of a bond or an amino acid sequence containing from 1 to 100 residues. The present invention also relates to a vaccine adjuvant comprising the immuno-therapy conjugate of the present invention. The present invention further relates to a method of reducing tumor growth, for inhibiting a viral infection and for improving immune response in a patient.

The present invention relates to a novel compound and its uses, which is an extract isolated and purified from Antrodia camphorate, in particular to 4-hydroxy-2,3 -dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone, and its use in tumor growth inhibition. The compound of the invention, which has never been discovered in Antrodia camphorate, can be applied in inhibiting the growth of cancer cells, such as breast cancer, hepatic cancer and prostate cancer; and be used as a pharmaceutical composition to inhibit the tumor growth; or further be applied in prevention of heart and blood vessel disease or dietary supplements for health needs through its antioxidant activity.

The present invention provides compositions and methods for increasing therapeutic gain in radiotherapy and chemotherapy for proliferating malignant or nonmalignant disease to produce high probability of tumor control with low frequency of sequelae of therapy by administering a therapeutically effective amount of a histone deacetylase inhibitor. The compounds are capable of simultaneously stimulating the epithelium regrowth, inhibiting the fibroblast proliferation, decreasing the collagen deposit, suppressing the fibrogenic growth factor, subsiding the proinflammatory cytokine and modulating the expression of cell cycle genes, tumor suppressors and oncogenes, and are useful to increase the therapeutic gain in radiotherapy and chemotherapy, which results in decrease of skin swelling and inflammation, promotion of epithelium healing in mucosa and dermis, decrease of xerostomia, prevention / reduction of severity of plantar-palmar syndrome, prevention of tissue fibrosis, ulceration, necrosis and tumorigenesis, and increase of tumor growth inhibition and tumor therapy effectiveness.

The invention discloses 14 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters shown in the general formula I. In the general formula I, AA represents L-Ser residue, L-Glu (OBzl) residue, L-Phe residue, L-Val residue, L-Arg residue, L-Tyr residue, L-Ala residue, L-Trp residue, L-Asn residue, L-Met residue, L-Ile residue, Gly residue, L-Asp (OBzl) residue or L-Leu residue. The invention discloses a preparation method of the 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters, discloses HT-29, K562, A549 and HL60 tumor cell growth inhibition effects of the 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters, further discloses S180-loading mice tumor growth inhibition effects of the 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters, and also discloses use of the 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters as antitumor drugs.

The present invention provides polynucleotides that encode the chemokine receptors 88-2B or 88C and materials and methods for the recombinant production of these two chemokine receptors. Also provided are assays utilizing the polynucleotides which facilitate the identification of ligands and modulators of the chemokine receptors. Receptor fragments, ligands, modulators, and antibodies are useful in the detection and treatment of disease states associated with the chemokine receptors such as atherosclerosis, rheumatoid arthritis, tumor growth suppression, asthma, viral infection, AIDS, and other inflammatory conditions.

The present invention relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing and / or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13 and ZFP236, respectively. The methods are useful in treating cancers and / or inhibiting tumor growth by enhancing expression of a gene that is validated as a target such as ICT1030, for protein, peptide drug and gene therapy modalities; or by RNA interference to silence and / or down-regulate targets such as ICT1024, ICT1025 and ICT1031 and ICB1003 that are validated for antibody, small molecule and other inhibitor drug modalities.

The invention relates to use of microbubbles with high-intensity cavitation generated by combining ultrasonic in preparation of anti-tumor neovascularization medicaments. The microbubbles are high-intensity cavitation effect microbubbles generating mechanical damage under the action of pulse-type high-peak negative pressure ultrasonic energy; and the ultrasonic energy has higher peak sound pressure and lower transmitting duty cycle. The generated high-intensity cavitation effect can generate obvious tumor microcirculation blocking effect on the tumor neovascularization, repeatedly perform deprivation therapy for further generating tumor growth inhibition, and reduce the transfer rate of malignant tumors. The novel treatment use of the microbubbles is applied to the treatment of various solid malignant tumors and angiogenesis pathological changes and is brand new use of the microbubble with application prospect.

The peptides and precursors thereof, inclusive salts thereof, of the present invention are useful as a pharmaceutical composition, for example as therapeutic or prophylactic agents for hormone-producing tumors, acromegaly, gigantism, dementia, gastric ulcer and the like, hormone secretion inhibitors, tumor growth inhibitors, neural activity or sleep modulators, etc. The DNAs coding for the peptides or precursors of the invention are useful as a pharmaceutical composition, for example as agents for the gene therapy or prevention of hormone-producing tumors, acromegaly, gigantism, dementia, gastric ulcer and the like, hormone secretion inhibitors, tumor growth inhibitors, neural activity or sleep modulators, etc. Furthermore, the DNAs coding for the peptides or precursors of the invention are useful as agents for the gene diagnosis of various diseases, for example, hormone-producing tumors, acromegaly, gigantism, dementia, gastric ulcer, etc. The antibodies against the peptides, precursors or salts of the invention can be used for assaying the peptides, precursors or salts of the invention in test solutions. The peptides, precursors or salts of the invention are useful as reagents for screening for compounds, or salts thereof, capable of modifying the binding of the peptides, precursors or salts of the invention to certain receptors.

The disclosure provides, e.g., enucleated erythroid cells comprising an amino acid degradative enzyme such as asparaginase and a targeting moiety such as an anti-CD33 antibody molecule. The cells may be used, e.g., to treat cancers such as AML.

The present invention relates to compositions and methods for preventing and treating a condition in a mammalian subject that include at least one inhibitor of double stranded RNA dependent protein kinase (PKR-I) prior to or concurrently with the treatment, wherein the treatment results to an inhibition of activation of dsRNA-dependent protein kinase. The compositions and methods of the present invention further include at least one potentiator that further enhances the inhibition of phosphorylation by PKR-I.

The present invention relates to a series of dicarboxylic acid ester derivatives of ginsenosides such as succinate and glutarate derivatives of 20-O-β-D-glucopyranosyl-protopanaxadiol (compound K, abbreviated as CK), preparation thereof and pharmaceutical uses thereof. The dicarboxylic acid ester derivatives of ginsenosides of the present invention can be used to form pharmaceutical acceptable salts thereof having a high water solubility or can be directly dissolved in an aqueous solution of metal salt, and retain the pharmaceutical activities of ginsenosides such as tumor growth inhibition and cancer preventive cytotoxicity. The dicarboxylic acid ester derivatives of ginsenosides of the present invention are thus suitable for use in the manufactures of various pharmaceutically and cosmetically acceptable dosage forms of preparations, such as peripheral, oral, and topical dosage forms.

CD44, the receptor for hyaluronic acid, has complex functions in cellular physiology, cell migration and tumour metastasis. The inventors have previously found that human CD44 receptor overexpression in mouse fibrosarcoma cells inhibits subcutaneous tumour growth in mice [Kogerman et al., Oncogene 1997; 15:1407-16; Kogerman et al., Clin Exp Metastasis 1998; 16:83-93]. Here it is demonstrated that a tumour growth inhibitory effect of CD44 is caused by block of angiogenesis. Furthermore, the inventors have found that soluble recombinant CD44 hyaluronic acid binding domain (CD44HABD) inhibits angiogenesis in vivo in cLick and mouse and thereby inhibits human tumour growth of various origins. The anti-angiogenic effect of CD44-HABD is independent of hyaluronic acid (HA) binding, since non-HA-binding mutants of CD44HABD still maintain anti-angiogenic properties. The invention discloses soluble CD44 recombinant proteins as a novel class of angiogenesis inhibitors based on targeting of vascular cell surface receptor. A method of block of angiogenesis and treatment of human tumours using recombinant CD44 proteins as well as their analogues is disclosed. As a further embodiment of the invention, methods for screening for new drug targets using CD44 recombinant proteins and their analogues is presented.

The invention relates to a human reforming mouse ING4 (tumor growth inhibition factor) gene and recombinant adenovirus (adenovirus hominis 5 shape Ad-ING4-DeltaGFP), wherein preservation cooperation is Chinese typical culture preservation centre, preservation number is CCTCC-V200701. The invention also relates to a human reforming gene mutation technique, adenovirus transition carrier removing GFP and homologous recombinant adenovirus carrier. The ING4 gene and recombinant adenovirus carrier provide new immunodiagnosis and target therapeutic approach for treating neoplastic disease, development disease, immune disease, the other disease owing to abnormal expression of tumour growth inhibition factor ING4, special cancer of the lungs and leukocythemia, which is provided with a giant application prospect.

Described herein is the use of phage display antibody engineering technology and synthetic peptide screening to identify SDl and SD2, human single-domain antibodies to mesothelin. SDl recognizes a conformational epitope at the C-terminal end (residues 539-588) of human mesothelin close to the cell surface. SD2 binds full-length mesothelin. To investigate SDl as a potential therapeutic agent, a recombinant human Fc (SDl-hFc) fusion protein was generated. The SDl-hFc protein exhibits strong complement-dependent cytotoxicity (CDC), in addition to antibody- dependent cellular cytotoxicity (ADCC), against mesothelin-expressing tumor cells. Furthermore, the SDl-hFc protein causes significant tumor growth inhibition of tumor xenografts in nude mice. SDl and SD2 are the first human single-domain antibodies targeting mesothelin-expressing tumors.

The present invention relates to a system and method for the photomodulation of living tissue. When photomodulated, living tissue will exhibit bioactivation or bioinhibition according to the present invention and, when using the disclosed sources of narrowband multichromatic radiation can cause significant dermatologic advantages such as hair removal, hair growth stimulation, wrinkle reduction, acne reduction and scar removal, vitiligo, etc. The present invention has application to non-dermatological medical treatments including tumor growth inhibition, cell regeneration, the stimulation of tissue in organs, etc.

It is intended to provide anticancer therapy using autologous cells or the like, which induces the regression of cancer or has favorable drug delivery effects and brings about reduction or withdrawal of a hypoxic region(s) in tumor. Transplantation of endothelial progenitor cells, via intravenously or other methods leads to tumor growth inhibition, an increase of the vascular density with an enlargement of the vascular diameter, and reduction of a hypoxic region(s) in the tumor. Allogeneic transplantation of endothelial progenitor cells may be achieved to secure the cells for the therapy, however, autologous transplantation of endothelial progenitor cells from cancer patients would be desirable in order to evade rejection. When the autologous cells are used, mononuclear cells are separated from the peripheral blood or bone marrow of the patient and cultured using an endothelial differentiation medium containing cytokines such as VEGF to obtain adherent cells, which can then be collected and advantageously used as endothelial progenitor cells.

The invention discloses a mercaptyl-terminated (2-dimethylamino ethyl) polymethacrylic ester polymer, a self-assembled and modified nano-gold compound (PDMAEMAGNPs) of the polymer as well as a compound of the polymer and plasmid DNA; and the invention also discloses preparation methods of the polymer and the compounds as well as the application of all in carrier as genes. When the concentration ofthe compounds of PDMAEMAGNPs and GFP DNA (green fluorescent protein expression DNA) is 30Mug / mL, the transfection efficiency to HEK 293T cell is 30 percent, and the survival rate to HEK 293T cell, HeLa cell and 293 cell is more than 80 percent. The PDMAEMAGNPs / CpG ODN (human CpG oligodeoxynucleotide) compound has remarkable effects in gene therapy in vitro and in vivo. The suppression ratio to tumor growth of the PDMAEMAGNPs / p53 DNA (tumor suppressor gene) is 30-37 percent.

The invention relates to a codon-optimized gene of a 16-type L2E7 recombinant protein of human papilloma virus (HPV), which can be expressed efficiently in colibacillus. The optimized gene can be expressed efficiently by being inserted in a prokaryotic expression vector pET9a, and the expression level accounts for 50% of all viruses; an expression protein is immune to mice after being purified. Proved by experiment results, the protein has the same immunogenicity with a protein which is not expressed by the optimized gene and can induce the release of specific gamma-1NF; proved by tumor growth inhibition animal experiments, protein immunity has evident inhibition effect on tumor growth and the growth of 90% of mouse tumor cells can be inhibited completely. The prokaryotic high-efficiency expression system of L2E7 recombinant protein, which is established by the optimized gene, can be used in the pilot scale production and drug discovery of preventive and curative vaccines of HPV16 infection and relevant cervical carcinoma.

The invention relates to an application of Trichoderma pseudokoningii extracellular polysaccharides having anticancer activities. The Trichoderma pseudokoningii extracellular polysaccharides having the anticancer activities can reduce the vitality of K562 cells in vitro when they are applied to tumor growth inhibition (auxiliary) medicines, so intracellular active oxygen and free calcium ion concentrations are improved, the expression abundance of mRNA of p53 and Bax genes is improved, the expression of the Bc1-2 transcription level is reduced, the ectropion of cell membrane phosphatidylserine of the human chronic granulocyte leukemia cells K562 is induced, and the nuclear polycondensation and the fragmentation of K562 are induced to generate apoptotic bodies and apoptosis; and in-vivo administration can increase weights of tumor bearing mice and alleviate growth speeds and weights of tumors of the tumor bearing mice, thereby tumor cell killing and tumor growth inhibiting purposes are reached.

The invention relates to methods for inhibiting gene silencing, methods for inhibiting cell proliferation, methods for inhibiting Ras mediated tumor growth, methods for screening for regulators of FAS expression, and methods for identifying inhibitors of Ras mediated tumor growth.

The invention discloses a chromone skeleton-containing polycyclic compound as well as a preparation method and application thereof. The preparation method comprises the following steps: with 3-iodochromone compounds and norbornene as building blocks and palladium acetate as a catalyst, carrying out a [2 + 2 + 1] domino cycloaddition reaction with benzyl bromide compounds in an organic solvent to obtain a series of polycyclic compounds containing chromone skeletons, wherein diastereostereoselective change of the product is realized by adjusting the solvent. The chromone skeleton-containing polycyclic compound contains a chromone skeleton with potential biological activity, can provide a compound source for biological activity screening, and has important application value for drug screeningand pharmaceutical industry. Meanwhile, tumor growth inhibition activity screening is carried out on human non-small cell lung cancer cells (A549) and human hepatoma carcinoma cells (HepG2) of two tumor cell strains by the compound, and the compound is found to have certain tumor cell growth inhibition activity and can be applied to preparation of anti-tumor drugs.

The invention discloses a preparation method for a fluorescent star-shaped block copolymer and application of the fluorescent star-shaped block copolymer serving as a medicine carrier. According to the preparation method, the fluorescent star-shaped block copolymer is prepared according to ring opening polymerization by taking amphipathic polylactic acid-polyphosphoester as an arm and taking a perylene bisimide derivative as a core. The fluorescent star-shaped block copolymer is self-assembled in an aqueous solution to form fluorescent supramolecular micelles, have good fluorescence characteristics, and can serve as a fluorescent probe and be used for cell and in-vivo imaging. The fluorescent supramolecular micelles prepared by the preparation method can effectively carry hydrophobic medicines and realize pH stimulation release. The analysis of a laser scanning confocal microscope and a flow cytometer show that the fluorescent supramolecular micelles are easily swallowed by cancer cells and can realize cellular internalization. In in-vitro and in-vivo tumor growth inhibition experiments, compared with a free medicine, the inhibition effect of the fluorescent supramolecular micelles to tumor growth is more obvious, so that the fluorescent supramolecular micelles have potential application value in the fields of biological imaging and cancer treatment.

The invention relates to designing and application of a prodrug based on a gemcitabine structure. According to the prodrug, a phosphate ester long-chain group is introduced to the position 5'-OH of a gemcitabine five-membered sugar ring, so fat-solubility and membrane permeability of the prodrug are improved. In tumors lacking nucleic acid transport protein, the fat-soluble prodrug can enter the tumors through passive diffusion and active transport to inhibit growth of the tumors. Moreover, the prodrug can be orally taken, thereby obtaining a better or same curative effect of tumor growth inhibition compared with intraperitoneal injection of gemcitabine.

The invention discloses application of artemisia absinthium extract to preparing anti-hepatoma medicine. According to the application of the artemisia absinthium extract to preparing the anti-hepatomamedicine, hepatoma cell apoptosis is caused by inducing endoplasmic reticulum stress and mitochondria dependency path through active oxygen generation in artemisia absinthium alcohol extract and petroleum-ether and ethyl-acetate extract, and growth of hepatoma cells is inhibited; the inhibition rate of the artemisia absinthium alcohol extract for internal tumor growth reaches 60% or above, and the inhibition rate of the petroleum-ether and ethyl-acetate extract for tumor growth reaches 80% or above.

The invention discloses a drug-loaded polymer vesicle with an asymmetric membrane structure, a preparation method and application in preparation of a drug for treating acute myeloid leukemia. An amphiphilic triblock polymer with polyaspartic acid PAsp, a targeted amphiphilic block polymer and a small molecule drug are assembled together to prepare the targeted small molecule drug-loaded polymer vesicle with the asymmetric membrane structure. The drug-loaded polymer vesicle disclosed by the invention has many unique advantages, including small size, simple and controllable preparation, reversible crosslinking, in-vivo stability, targeted delivery, high intracellular drug enrichment concentration, sensitive reduction, efficient killing of tumor cells, significant tumor growth inhibition effect and the like, and especially the drug-loaded vesicle disclosed by the invention has effective inhibition on both acute myeloid leukemia cell lines and patient cells. Therefore, the polymer vesicleis expected to become a simple and multifunctional nano platform for efficient and specific targeted delivery of drugs to tumor cells.

The invention relates to the technical field of medicine, in particular to an application of a cumarins compound in preparing medicine for inhibiting tumor growth. The cumarins compound refers to 3-[4-(3- isopentyloxy) benzamido] coumarin and derivatives thereof, including pharmaceutically acceptable salt; the general formula of the chemical structure of the cumarins compound is as follows: group R1, group R2, group R3, group R4 are respectively selected from saturated or unsaturated alkyl radical, C3-C7 cyclic hydrocarbon radical, phenmethyl, aromatic radical or 5-7-membered heterocyclic radical of hydrogen, halogen, C1-C6 straight chain or branched chain; X is selected from saturated or unsaturated alkyl radicals of O, NR6, S; R6 is selected from saturated or unsaturated alkyl radical, C3-C7 cyclic hydrocarbon radical, phenmethyl, aromatic radical or 5-7-membered heterocyclic radicals of hydrogen, halogen, C1-C6 straight chain or branched chain; R5 is selected from H, C1-C6 alkyl radical, phenyl, substitute phenyl, phenmethyl, aralkyl and so on. As proved by the vitro assay, the cumarins compound of the invention can be used for preparing medicine for inhibiting tumor growth.

The present invention relates to compositions and methods for preventing and treating a condition in a mammalian subject that include at least one inhibitor of double stranded RNA dependent protein kinase (PKR-I) prior to or concurrently with the treatment, wherein the treatment results to an inhibition of activation of dsRNA-dependent protein kinase. The compositions and methods of the present invention further include at least one potentiator that further enhances the inhibition of phosphorylation by PKR-I.

The invention relates to a method for improving the anticancer activity for Codonopsis lanceolata Benth.et Hook.F, which comprises: slicing or homogenizing fresh Codonopsis lanceolata Benth.et Hook.F, or crushing dry Codonopsis lanceolata Benth.et Hook.F, or powdering the dry Codonopsis Lanceolata Benth.et Hook.F; soaking in water; sterilizing under a high pressure; adding 0.5 to 5.0 percent of active yeast and 1 to 8 percent of glucose under a sterile condition when the temperature lowers to 30 DEG C; fermenting at 20 to 37 DEG C for 1 to 10 days, and adding a polar solvent after fermentation to extract for 5 to 24 hours at 0 to 100 DEG C; and filtering, recovering solvent and concentrating under reduced pressure or drying by freezing. The method can improve the inhibition effect of Codonopsis lanceolata Benth.et Hook.F on the growth of tumors.

A method of increasing immunity of a subject by administering an antidepressant to the subject is disclosed in the present invention. Preferably, the antidepressant is mirtazapine. And further, another object of the present invention is related to a method of administering the abovementioned antidepressant to the subject for treating cancer. The present invention tries to find the mechanism of the tumor growth inhibition by mirtazapine, and it may be due to the alteration of the tumor microenvironment, which involves the activation of the immune response and the recovery of serotonin level.

The present invention discloses a use of a miR-9 inhibitor in preparation of tumor growth inhibition drugs. According to the present invention, the modern biology technology is adopted, and it is found that the miR-9 has the use of regulation of MDSC cells, wherein immunosuppression capability of MDSC cells can be down-regulated by inhibiting miR-9 expression in MDSC cells so as to inhibit tumor growth, such that the miR-9 can be adopted as a target for tumor treatment so as to provide potential application values and practical significance for tumor immunotherapy.